ERBB4: A Potential Drug Target and Biomarker for Various Diseases

Target Name: ERBB4

NCBI ID: G2066

ERBB4

ERBB4: A Potential Drug Target and Biomarker for Various Diseases

ERBB4 (ErbB4) is a transmembrane protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. Its primary function is to regulate cell proliferation and survival, and it is a potential drug target in various diseases.

The ERBB4 gene was identified in 1997 and has since been shown to encode a 180-kDa protein that is expressed in various tissues. The protein is composed of a transmembrane region and a cytoplasmic region that contains a unique N-terminal region. The N-terminal region is rich in various domains, including a leucine-rich repeat (LRR), a cysteine-rich domain (CRD), and a carboxy-terminal domain (CTD).

The ERBB4 protein is involved in various signaling pathways, including the cell proliferation signaling pathway, the neurotrophin signaling pathway, and the TGF-β signaling pathway. It is a potent inhibitor of the neurotrophin receptor TrkB, which is a key regulator of neuronal survival and proliferation. The ERBB4 protein has been shown to inhibit TrkB-mediated signaling in various cell types, including neurons, astrocytes, and microglia.

The ERBB4 protein is also involved in the regulation of cell adhesion and migration. It has been shown to play a role in the regulation of tight junction formation in epithelial cells and in the regulation of cancer cell migration. The ERBB4 protein is also involved in the regulation of cell survival and has been shown to play a role in the regulation of cell cycle progression.

The ERBB4 protein is a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. One of the main reasons for its potential as a drug target is its involvement in various signaling pathways that are involved in the development and progression of these diseases. For example, the ERBB4 protein is involved in the regulation of cell proliferation and survival, which are key factors in the development of cancer. It is also involved in the regulation of neurotrophin signaling, which is involved in the development and progression of neurodegenerative diseases.

In addition to its involvement in signaling pathways, the ERBB4 protein is also a potential biomarker for various diseases. The ERBB4 protein is expressed in various tissues and has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that the ERBB4 protein may be a useful biomarker for the diagnosis and treatment of these diseases.

The ERBB4 protein is also a potential target for small molecules, including inhibitors of the neurotrophin receptor TrkB. Several studies have shown that inhibitors of TrkB can be effective in treating neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The ERBB4 protein is also involved in the regulation of neurotrophin signaling, which makes it a potential target for neurotrophin inhibitors.

In conclusion, ERBB4 is a transmembrane protein that is involved in various signaling pathways and is a potential drug target and biomarker in various diseases. Its functions include regulating cell proliferation and survival, cell adhesion and migration, and neurotrophin signaling. The ERBB4 protein is a potential target for small molecules, including inhibitors of the neurotrophin receptor TrkB, and has been shown to be involved in the regulation of cell cycle progression, tight junction formation, and cancer cell migration. Further research is needed to fully understand the functions of the ERBB4 protein and its potential as a drug target and biomarker.

Protein Name: Erb-b2 Receptor Tyrosine Kinase 4

Functions: Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis

The "ERBB4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERBB4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets